Study Comparing AEZS-108 to Doxorubicin as a Second Line Therapy of Endometrial Cancer

Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin. The study will include about 500 patients with endometrial cancer resistant to platinum/taxane-based chemotherapy.